[go: up one dir, main page]

MX2019001577A - Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. - Google Patents

Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.

Info

Publication number
MX2019001577A
MX2019001577A MX2019001577A MX2019001577A MX2019001577A MX 2019001577 A MX2019001577 A MX 2019001577A MX 2019001577 A MX2019001577 A MX 2019001577A MX 2019001577 A MX2019001577 A MX 2019001577A MX 2019001577 A MX2019001577 A MX 2019001577A
Authority
MX
Mexico
Prior art keywords
lysosomal storage
pharmaceutical compositions
storage disorders
uses directed
directed
Prior art date
Application number
MX2019001577A
Other languages
English (en)
Other versions
MX384447B (es
Inventor
Strupp Michael
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019001577(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1613828.1A external-priority patent/GB201613828D0/en
Priority claimed from GBGB1702552.9A external-priority patent/GB201702552D0/en
Priority claimed from GBGB1705762.1A external-priority patent/GB201705762D0/en
Priority claimed from GBGB1706854.5A external-priority patent/GB201706854D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MX2019001577A publication Critical patent/MX2019001577A/es
Publication of MX384447B publication Critical patent/MX384447B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona el tratamiento de los trastornos del almacenamiento lisosomal (LSD), que comprende administrar acetil-leucina o una sal farmacéuticamente aceptable de la misma.
MX2019001577A 2016-08-11 2017-08-11 Composiciones farmacéuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. MX384447B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1613828.1A GB201613828D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for lysosomal storage disorders
GBGB1702552.9A GB201702552D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for lysosomal storage disorders
GBGB1705762.1A GB201705762D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for lysosomal storage disorders
GBGB1706854.5A GB201706854D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for lysosomal storage disorders
PCT/IB2017/054928 WO2018029657A1 (en) 2016-08-11 2017-08-11 Pharmaceutical compositions and uses directed to lysosomal storage disorders

Publications (2)

Publication Number Publication Date
MX2019001577A true MX2019001577A (es) 2019-08-29
MX384447B MX384447B (es) 2025-03-14

Family

ID=59859423

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019001577A MX384447B (es) 2016-08-11 2017-08-11 Composiciones farmacéuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
MX2021008432A MX2021008432A (es) 2016-08-11 2019-02-07 Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021008432A MX2021008432A (es) 2016-08-11 2019-02-07 Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.

Country Status (28)

Country Link
US (3) US11400067B2 (es)
EP (4) EP3482754B1 (es)
JP (3) JP7393943B2 (es)
KR (4) KR20240110078A (es)
CN (1) CN109843275A (es)
AU (3) AU2017308864B2 (es)
CA (1) CA3033557A1 (es)
CY (2) CY1121345T1 (es)
DK (2) DK3359146T3 (es)
ES (2) ES2849566T3 (es)
HK (1) HK1253282B (es)
HR (2) HRP20190344T1 (es)
HU (2) HUE041914T2 (es)
IL (2) IL314107A (es)
LT (2) LT3482754T (es)
MA (2) MA43876B1 (es)
MD (2) MD3482754T2 (es)
ME (1) ME03340B (es)
MX (2) MX384447B (es)
PL (2) PL3359146T3 (es)
PT (2) PT3359146T (es)
RS (2) RS61442B1 (es)
RU (2) RU2749515C2 (es)
SG (1) SG11201901048VA (es)
SI (2) SI3482754T1 (es)
SM (2) SMT202100050T1 (es)
TN (1) TN2019000032A1 (es)
WO (1) WO2018029657A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61442B1 (sr) 2016-08-11 2021-03-31 Intrabio Ltd Farmaceutske kombinacije i upotrebe usmerene na poremećaje lizozomalnog skladištenja
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
CN113348018B (zh) 2018-12-06 2025-04-01 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
MX2021010568A (es) 2019-03-02 2021-11-12 Intrabio Ltd Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades.
EP3989962B1 (en) 2019-06-28 2025-08-27 IntraBio Ltd Combination therapy with acetyl-leucine and miglustat for treating a lysosomal storage disease
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2749512B1 (fr) * 1996-06-10 1999-08-13 Pf Medicament Utilisation de l'acetyl dl leucine pour le traitement des tremblements
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
FR2883180B1 (fr) 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
WO2009114729A2 (en) * 2008-03-14 2009-09-17 Irm Llc Compounds, compositions and methods for treating lysosomal storage diseases and disorders
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
GB201114017D0 (en) * 2011-08-15 2011-09-28 Univ Dundee Inhibitors against endosomal/ysosomal enzymes
US20150147309A1 (en) * 2012-06-06 2015-05-28 Fondazione Telethon Allosteric chaperones and uses thereof
KR102247701B1 (ko) 2016-02-26 2021-05-03 한미정밀화학주식회사 폴리에틸렌글리콜 디알데히드 유도체의 제조방법
RS59048B1 (sr) 2016-08-11 2019-08-30 Intrabio Ltd Terapeutski agensi za neurodegenerativne bolesti
RS61442B1 (sr) 2016-08-11 2021-03-31 Intrabio Ltd Farmaceutske kombinacije i upotrebe usmerene na poremećaje lizozomalnog skladištenja

Also Published As

Publication number Publication date
IL264610A (en) 2019-02-28
US20220331278A1 (en) 2022-10-20
IL314107A (en) 2024-09-01
RU2019106493A3 (es) 2020-10-26
KR20220154849A (ko) 2022-11-22
TN2019000032A1 (en) 2020-07-15
JP7757446B2 (ja) 2025-10-21
KR20190039226A (ko) 2019-04-10
ES2716133T3 (es) 2019-06-10
ES2849566T3 (es) 2021-08-19
EP3482754B1 (en) 2020-12-23
SMT201900154T1 (it) 2019-05-10
SI3359146T1 (sl) 2019-05-31
HK1253282A1 (en) 2019-06-14
RU2021115932A (ru) 2021-06-08
US20240197663A1 (en) 2024-06-20
PL3482754T3 (pl) 2021-07-05
KR102412724B1 (ko) 2022-06-23
JP7393943B2 (ja) 2023-12-07
MD3359146T2 (ro) 2019-04-30
HK1253282B (en) 2020-02-07
MX2021008432A (es) 2021-08-19
JP2019524821A (ja) 2019-09-05
EP3359146B1 (en) 2019-01-23
HUE041914T2 (hu) 2019-06-28
MA55947A (fr) 2022-03-23
US12433863B2 (en) 2025-10-07
JP2024059863A (ja) 2024-05-01
JP2022050564A (ja) 2022-03-30
AU2023202903A1 (en) 2023-05-25
CA3033557A1 (en) 2018-02-15
IL264610B2 (en) 2024-12-01
EP4342461A2 (en) 2024-03-27
AU2017308864B2 (en) 2023-06-01
RU2019106493A (ru) 2020-09-11
CY1123844T1 (el) 2022-05-27
ME03340B (me) 2019-10-20
EP3865126A1 (en) 2021-08-18
MA43876A (fr) 2018-08-15
IL264610B1 (en) 2024-08-01
MX384447B (es) 2025-03-14
SI3482754T1 (sl) 2021-04-30
RS61442B1 (sr) 2021-03-31
EP3482754A1 (en) 2019-05-15
US11400067B2 (en) 2022-08-02
HRP20210153T1 (hr) 2021-05-28
US20190201359A1 (en) 2019-07-04
MA43876B1 (fr) 2019-04-30
EP4342461A3 (en) 2024-05-29
KR20220044372A (ko) 2022-04-07
PL3359146T3 (pl) 2019-07-31
PT3359146T (pt) 2019-03-27
KR20240110078A (ko) 2024-07-12
SMT202100050T1 (it) 2021-03-15
LT3482754T (lt) 2021-05-10
MD3482754T2 (ro) 2021-05-31
SG11201901048VA (en) 2019-03-28
CN109843275A (zh) 2019-06-04
HRP20190344T1 (hr) 2019-04-19
RU2749515C2 (ru) 2021-06-11
RS58478B1 (sr) 2019-04-30
AU2023202903B2 (en) 2025-03-06
PT3482754T (pt) 2021-02-03
WO2018029657A1 (en) 2018-02-15
HUE052837T2 (hu) 2021-05-28
AU2017308864A1 (en) 2019-02-21
LT3359146T (lt) 2019-04-25
US12433862B2 (en) 2025-10-07
BR112019002719A2 (pt) 2019-05-14
CY1121345T1 (el) 2020-05-29
KR102467953B1 (ko) 2022-11-16
AU2025203479A1 (en) 2025-05-29
DK3359146T3 (en) 2019-04-08
DK3482754T3 (da) 2021-02-01
EP3359146A1 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
CO2018013293A2 (es) Derivados de pirazolopirimidina como inhibidor de quinasa
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2019001575A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
CL2018002784A1 (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue.
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
CL2017000782A1 (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2017000742A1 (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
CL2017001904A1 (es) Composición para el tratamiento de enfermedad veno-oclusiva hepática.
SV2016005313A (es) Derivados de carboxamida
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2017003140A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.